Outcomes and endpoints in cancer trials: bridging the divide.
暂无分享,去创建一个
Katherine Karakasis | Deborah Collyar | Ian F Tannock | Mahesh K B Parmar | Stan Kaye | I. Tannock | M. Parmar | M. Sydes | A. Oza | M. Friedlander | D. Collyar | S. Kaye | Michelle K Wilson | Matthew R Sydes | Michael Friedlander | Amit M Oza | Diana T Chingos | Tony W Ho | Tony W. Ho | K. Karakasis | Diana T. Chingos | T. Ho | M. Wilson
[1] S. Kopetz,et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. , 2012, Cancer research.
[2] Razelle Kurzrock,et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.
[3] Richard J Stephens,et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial , 2007, The Lancet.
[4] K. Getz,et al. Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration. , 2013, The oncologist.
[5] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[6] E. Trimble,et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] J. Bergh,et al. Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden , 2011, Breast Cancer Research and Treatment.
[8] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[9] W. Oh,et al. Premature termination of genitourinary cancer clinical trials. , 2014 .
[10] P. Grigsby,et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Pearson,et al. The use and reporting of patient-reported outcomes in phase III breast cancer trials , 2013, Clinical trials.
[12] Richard Pazdur,et al. End points and United States Food and Drug Administration approval of oncology drugs. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Katherine Karakasis,et al. Outcomes and endpoints in trials of cancer treatment: the past, present, and future. , 2015, The Lancet. Oncology.
[14] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[15] P. Keegan,et al. Accelerated approval of oncology products: the food and drug administration experience. , 2011, Journal of the National Cancer Institute.
[16] R. Pazdur,et al. United States Food and Drug Administration Drug Approval Summary , 2004, Clinical Cancer Research.
[17] M. Friedlander,et al. Impact of oxaliplatin-induced neuropathy: a patient perspective , 2012, Supportive Care in Cancer.
[18] B. Glimelius,et al. Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Jian Jin,et al. Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.
[20] C. Bokemeyer,et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Woodcock,et al. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology. , 2010, The oncologist.
[22] M. Parmar,et al. Speeding up the Evaluation of New Agents in Cancer , 2008, Journal of the National Cancer Institute.
[23] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[24] A. Shields,et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Jacobus Pfisterer,et al. A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.
[26] B Nebiyou Bekele,et al. Generalizability of cancer clinical trial results , 2006, Cancer.
[27] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] F. Hirsch,et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] R. Coleman,et al. Endpoints in clinical trials: What do patients consider important? A survey of the Ovarian Cancer National Alliance. , 2013, Gynecologic oncology.
[30] R. Ozols,et al. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182‐ICON5 , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[31] Richard Pazdur,et al. Endpoints for assessing drug activity in clinical trials. , 2008, The oncologist.
[32] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[33] D. Miles,et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] A. Oxman,et al. Systematic review to determine whether participation in a trial influences outcome , 2005, BMJ : British Medical Journal.
[35] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[36] M. King,et al. Patient-reported outcomes in ovarian cancer clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] D. Hershman,et al. Cracking open window of opportunity trials. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Jeffrey M. Fowler,et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer , 2012 .
[40] Gary D Bader,et al. International network of cancer genome projects , 2010, Nature.
[41] Thomas J. Smith,et al. Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small , 2010, Clinical Cancer Research.
[42] Lisa Wang,et al. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Government regulations and the use of drugs. , 1967, California medicine.
[44] R. Gray,et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy , 2013, Cancer.
[45] E. Cook,et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review , 2004, The Lancet.
[46] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[47] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] M. Parmar,et al. Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial , 2013, BJU international.
[49] I. Tannock,et al. Evaluation of treatment benefit: randomized controlled trials and population-based observational research. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] J. Berlin,et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] A. Bezjak,et al. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers , 2011, Quality of Life Research.
[52] D. Moher,et al. Reporting quality of life in clinical trials: a CONSORT extension , 2011, The Lancet.
[53] J. Blessing,et al. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma , 1983, Cancer.
[54] K. Carson,et al. Long-term corticosteroid replacement and bone mineral density in adult women with classical congenital adrenal hyperplasia. , 2006, The Journal of clinical endocrinology and metabolism.
[55] Noel W Clarke,et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. , 2014, European urology.
[56] R. Wahl,et al. Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy , 2009 .
[57] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[58] V. Lemmens,et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] R. Kurzrock,et al. Fool’s gold, lost treasures, and the randomized clinical trial , 2013, BMC Cancer.
[60] J. Berek,et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] M. Junttila,et al. Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.
[62] R. D'Agostino. Changing end points in breast-cancer drug approval--the Avastin story. , 2011, The New England journal of medicine.
[63] Daniel J Sargent,et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Mark J. Ratain,et al. Tumour heterogeneity in the clinic , 2013, Nature.
[65] M. Parmar,et al. Evaluating many treatments and biomarkers in oncology: a new design. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] Kristine R Broglio,et al. Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.
[67] Tiffany Shao,et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] M. Parmar,et al. STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).
[69] Cassandra Willyard. 'Basket studies' will hold intricate data for cancer drug approvals , 2013, Nature Medicine.
[70] A. Bottomley,et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[72] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[73] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[74] A. Luini,et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[76] I. Tannock,et al. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence , 2014, British Journal of Cancer.
[77] J. Yi,et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] E. Yordan,et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study , 1986, Cancer.
[79] David Moher,et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. , 2013, JAMA.
[80] Lesley Seymour,et al. Tumor Shrinkage and Objective Response Rates: Gold Standard for Oncology Efficacy Screening Trials, or an Outdated End Point? , 2009, Cancer journal.
[81] James S. Duncan,et al. The dynamic nature of the kinome. , 2013, The Biochemical journal.
[82] Kevin Carroll,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.
[83] C. Sander,et al. Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.
[84] J. Haaga,et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[85] I. Tannock,et al. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[86] V. Miller,et al. Novel clinical trial designs for the development of new antiretroviral agents , 2012, AIDS.
[87] G. Henderson,et al. What Research Ethics Should Learn from Genomics and Society Research: Lessons from the ELSI Congress of 2011 , 2012, Journal of Law, Medicine & Ethics.
[88] I. Tannock,et al. The transition from phase II to phase III studies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] M. Parmar,et al. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial , 2012, Trials.
[90] M. Ando,et al. Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction. , 2014, Clinical lung cancer.
[91] G. Salles,et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] I. Tannock,et al. Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] R. Kurzrock,et al. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] R. Kurzrock,et al. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] Diane P. Martin,et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. , 2014, Journal of the National Cancer Institute.